SITC Cancer Immunotherapy Guidelines – Renal Cell Carcinoma Webinar

When:  Jan 7, 2020 from 11:00 to 12:00 (ET)

On Jan. 7, 2020, join leading experts in cancer immunotherapy as they present an overview of the recently published SITC Cancer Immunotherapy Guidelines – Renal Cell Carcinoma at a live webinar.

18CIG-logo-rgb.jpgThis FREE CME-, CNE-, CPE-certified webinar provides a chance for healthcare providers who treat cancer patients, including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants to learn about the recommendations from the published guideline on immunotherapy for the treatment of renal cell carcinoma.

The webinar faculty will present and discuss: 

  • SITC's Cancer Immunotherapy Guidelines on immunotherapy for the treatment of renal cell carcinoma
  • New FDA approvals and the role of patient biomarker testing in optimizing treatment selection
  • Unique case studies that may require adaptation of cancer immunotherapy regimens
  • How best to manage immune-related adverse events

A dedicated question-and-answer session during the webinar provides an opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.

Webinar Faculty: 
Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Dena Battle – KCCure
David McDermott, MD – Beth Israel Deaconess Medical Center
Brian Rini, MD – Vanderbilt University Medical Center

Webinar Agenda:
11:00–11:05 a.m. EST  Overview: welcome and introductions
11:05–11:40 a.m. EST  Presentation and discussion of guideline content 
11:40–11:55 a.m. EST  Question and answer session
11:55 a.m.–Noon EST  Closing remarks

Continuing Education Credit Information:
Continuing Education Credits are available for physicians, nurses and pharmacists. To view full accreditation information, click here

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer

This webinar is supported, in part, by independent medical education grant funding from Amgen, AstraZeneca Pharmaceuticals LP, Celgene Corporation and Merck & Co., Inc.

#CME #CPE #Webinar #Oncologist #Clinician #RegisteredNurse #Pharmacist #AdverseEvents #CancerImmunotherapyGuidelines #PhysicianAssistant #NursePractitioner #RenalCellCarcinoma